| observations demonstrate MALT1 represses genes activating the aggressive phenotype of carcinoma cells, and MALT1 acts as a tumour suppressor and the loss of expression stimulates oral carcinoma progression | oral |
| Protease activity of the API2-MALT1 fusion oncoprotein in MALT lymphoma development and treatment. | lymphoma, |
| Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice. | lymphoma, |
| Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation. | None |